Overview

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Morphine
Naltrexone